The company develops an unique POC testing platform capable of testing antibodies, antigens and small molecule targets simultaneously.
HeMemics Biotechnologies, Inc. has raised $250K in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in March 2025.
HeMemics Biotechnologies, Inc.'s investors include TEDCO, AMVI Partners.
HeMemics Biotechnologies, Inc. is headquartered in Gaithersburg, United States.
The company develops an unique POC testing platform capable of testing antibodies, antigens and small molecule targets simultaneously.
HeMemics Biotechnologies, Inc. is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"HeMemics Biotechnologies, Inc. — Funding & Investors." VCBacked, March 19, 2025, https://www.vcbacked.co/company/hememics-biotechnologies-inc. Accessed September 18, 2026.
VCBacked. (2025). HeMemics Biotechnologies, Inc. — Funding & Investors. Retrieved September 18, 2026, from https://www.vcbacked.co/company/hememics-biotechnologies-inc
{{cite web |title=HeMemics Biotechnologies, Inc. — Funding & Investors |url=https://www.vcbacked.co/company/hememics-biotechnologies-inc |website=VCBacked |access-date=September 18, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated